UK Markets close in 1 hr 48 mins

Genmab A/S (GNMSF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
344.28-5.90 (-1.68%)
As of 02:02PM EST. Market open.
Sign in to post a message.
  • H
    H
    Charles, seems like we are the only ones following this company. I found it when I bought BMEZ, that is a blackrock closed end fund , pays about 7%, should be a good one to own next year, anyway I found that GMAB is the top holding in that fund, what does that tell you?
  • B
    Bunny
    Management has increased the guidance for the year ! The growth is continuing with few major big pharms are using GMAB platform. Go to their web site to see the impressive list of big pharmaceutical companies are relying on GMAB platform and will co sharing profits and paying milestone money to GMAB. It is the best business model with low costs of capital with lots of exponentially growth in the proven gene therapy and cancer treatment fields.
  • B
    Bunny
    Bullish Put Call ratio is at 0.14, dropping from 0.46. Fund holdings are increasing.
  • B
    Bunny
    My target price is 57 to 65 dollars in the short term. In the long term, the growth could be exponential.
  • K
    Kroptie
    Even Pipeline expanding. genmab is like a mutual find of biotech with over 20 candidates over 33 different indications
  • K
    Kroptie
    When JNJ took out Actelion for $30 billion it had no earnings and paid $280 a share. Genmab has $250 million USD net income already and is valued at only 6 billion.Putting same price on Genmab would be $500
  • J
    James
    It look be just a matter of time until someone takes this company out. Great pipeline/no debt and plenty of cash on hand. Just hold and wait.
  • J
    James
    Looks like things are starting are starting to heat up. Horizon report on may 5th be interesting and seeing how the Tepezza sales are going. I have a feeling in 2 years this stock price will double as there is a lot coming down the pipeline just my gut from what I have been reading
  • M
    ML
    Copenhagen, Denmark; January 15, 2021 – Genmab A/S (Nasdaq: GMAB) announced today that the U.S. Food and Drug Administration (U.S. FDA) has approved the use of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj), a subcutaneous formulation of daratumumab, in combination with bortezomib, cyclophosphamide, and dexamethasone (VCd) for the treatment of adult patients with newly diagnosed light-chain (AL) amyloidosis.
  • D
    Div
    Great pipeline and Darzalex Fast Pro off to a good start even during Covid. Can’t get a better pipeline and already in the black for a young US company- IPO wasn’t that long ago! Long and strong/ forget that sell side today!! Want to get the shares cheaper as the analysts wake up to a great company!!
  • B
    Bunny
    Free Cash Flow increasing from 1.2 billions to over 6 billions DKK. That is almost 600% jump with further growth and recurring revenue ! This is a super growth stock. Stock price will jump.
  • I
    Imme
    What is this ...GMAB gets FDA approval on an MS drug and no market reaction??? I just bought some... hoping for markets react positively....
  • S
    Stocks Technical
    Hoping for this GMAB bounce intraday. Nice mention alongside a few cancer stocks today so I'm happy so far https://valuemarket.exchange/45r6sh
  • K
    Kroptie
    I listened to conference. Newest Darzulex indication just approved by FDA yesterday could double royalty income from JNJ in coming year
  • W
    William
    dont know why this didnt move on the abbvie news.
  • K
    Kroptie
    Split shares because management feels undervalued
  • P
    Peter K.
    The Hubrecht Institute and Genmab have developed a new robot, the STRIP-1 – test robot (Systematic Testing with Robotics & Innovation in Pandemic), capable of processing around 20,000 samples per 24 hours for SARS-CoV-2 testing, which means faster processing in a short duration of time. https://youtu.be/fE-4Krgjl54
  • W
    William
    Just sit tight. One approval after another this stock will be great! I admit I just rang the tegister for 100 shares but I'm holding the rest
  • K
    Kroptie
    The Alcyone study was very positive reducing mortality by 50%. these are huge numbers and the Chairman speaks very well of JNJ . JNJ took out Action for a big number. This is perennial rumored takeout by JNJ which partners with Genmab.Based on Action numbers Genmab is worth $500 or ADR of $250.
  • K
    Kroptie
    Fda approval and label expansion of Darzulex